Parodi O, Maseri A, Simonetti I
Br Heart J. 1979 Feb;41(2):167-74. doi: 10.1136/hrt.41.2.167.
A therapeutic trial with verapamil, a calcium-antagonist drug, was performed in 12 patients admitted to our coronary care unit because of frequent daily attacks of angina at rest attributed to coronary vasospasm. After a 48-hour run-in period, oral verapamil 480 mg/day and placebo were administered alternately during 4 randomised 48-hour periods. Transient ischaemic attacks with ST segment elevation or depression, with or without pain, were documented by continuous electrocardiographic monitoring. The number of attacks during the run-in and 2 placebo periods were 128, 123, and 130, respectively, and 31 and 23 during the 2 treatment periods (P less than 0.006 and P less than 0.003). This drug therefore appears to be effective in the management of patients with frequent attacks of angina at rest.
对12名因冠状动脉痉挛导致每日频繁静息性心绞痛发作而入住我们冠心病监护病房的患者进行了一项使用钙拮抗剂药物维拉帕米的治疗试验。在48小时的导入期后,在4个随机的48小时时间段内交替给予口服维拉帕米480毫克/天和安慰剂。通过连续心电图监测记录伴有或不伴有疼痛的ST段抬高或压低的短暂性缺血发作。导入期和2个安慰剂期的发作次数分别为128次、123次和130次,2个治疗期分别为31次和23次(P<0.006和P<0.003)。因此,这种药物似乎对频繁发作静息性心绞痛的患者有效。